Kraft Group, Roche and Novartis are in line for exits after small molecule drug developer C4 filed for a $100m offering,

US-based small molecule therapy developer C4 Therapeutics has filed to raise up to $100m in an initial public offering that would enable pharmaceutical firms Roche and Novartis and conglomerate Kraft Group to exit. C4 is developing treatments for diseases including cancer and various neurodegenerative disorders that are designed to work by degrading disease-causing proteins. Part…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.